---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-24-000045"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:20:12.851977+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharmaceuticals effects 1-for-8 reverse stock split to regain Nasdaq compliance

## Summary
- Reverse split effective 5:00 p.m. ET on June 14, 2024; trading on split-adjusted basis begins June 17.
- Shares outstanding reduced from ~4.7 million to ~0.6 million; new CUSIP 79400X404.
- Fractional shares paid in cash based on closing price on effective date; ticker SLRX unchanged.
- Split intended to meet Nasdaq $1.00 minimum bid price requirement; stockholders had approved ratio range 1:4 to 1:8.
- Authorized shares and par value unaffected; options and warrants adjusted proportionally.

## SEC filing metadata
- accession: 0001615219-24-000045
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000045/0001615219-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000045/flks-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-24-000045
- JSON: https://secwatch.observer/filing/0001615219-24-000045.json
- Plain text: https://secwatch.observer/filing/0001615219-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.